Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
8E11-CPT2 (UT Health Houston)
- Development stage
- Preclinical
- Lead developer
- University of Texas Health Science Center at Houston
- Modality
- Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
8E11-CPT2 (UT Health Houston): sourced facts only. name: "Furthermore, we have generated a camptothecin-based LGR5 ADC (8E11-CPT2) utilizing site-specific conjugation technology that demonstrates target- and dose-dependent cytotoxicity in CRC cells and was well-tolerated." [DOI:10.1158/1538-7445.am2025-2883]; target: "Furthermore, we have generated a camptothecin-based LGR5 ADC (8E11-CPT2) utilizing site-specific conjugation technology that demonstrates target- and dose-dependent cytotoxicity in CRC cells and was well-tolerated." [DOI:10.1158/1538-7445.am2025-2883]; developer: "UT Health Houston, Houston, TX." [DOI:10.1158/1538-7445.am2025-2883]; modality: "Furthermore, we have generated a camptothecin-based LGR5 ADC (8E11-CPT2) utilizing site-specific conjugation technology that demonstrates target- and dose-dependent cytotoxicity in CRC cells and was well-tolerated." [DOI:10.1158/1538-7445.am2025-2883]; stage: "Importantly, combination treatment of 8E11-CPT2 with CTX in RASmut CRC patient-derived xenograft models significantly reduced tumor burden with notable regression in some mice and extended survival compared to LGR5 ADC and CTX monotherapies." [DOI:10.1158/1538-7445.am2025-2883]
02
Targets
LGR5 (Leucine-rich repeat-containing G-protein coupled receptor 5)
Beyond the preview
Go deeper on 8E11-CPT2 (UT Health Houston).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 8E11-CPT2 (UT Health Houston).